DMRA Stock Forecast & Price Target

Damora Therapeutics is compelling because its lead program, DMR-001, targets the biologically validated mutCALR driver in ET and MF with selective Type 1 and Type 2 activity, no detectable wild-type CALR binding, and a once-monthly subcutaneous profile that could offer meaningful convenience versus incumbent IV or more frequent regimens. The company is also well capitalized, with about $540.5 million in cash and equivalents at 2Q26 expected to fund operations into 2H29, providing runway through mid-2027 proof-of-concept data and potentially into Ph 3 development as early as mid-2028. Beyond DMR-001, DMR-002 and DMR-003 add pipeline breadth and option value in a large underserved market, while the apparent opportunity to narrow Incyte’s lead through better subtype coverage and simpler dosing supports the positive fundamental view.

Damora Therapeutics is viewed negatively because its lead program faces a high-stakes mid-2027 Ph 1 POC readout that could fail to beat INCA033989’s response rates or to confirm acceptable SC Q4W tolerability and pharmacokinetics, leaving the company with little evidence of a differentiated product. The competitive backdrop is unfavorable: INCA033989 may already have a 2-3 year head start, and if it captures most of the addressable mutCALR population before DMR-001 arrives, Damora’s peak penetration would be difficult to achieve. Beyond competition, the company faces meaningful execution risk from IND delays, manufacturing issues, slower Ph 1 enrollment, or added regulatory data requests, while the broader field shows how difficult endpoint validation can be, as VAF remains unproven and prior trials such as SIMPLIFY-1 and PROUD-PV produced mixed or negative outcomes.